Literature DB >> 12396886

Daniel Vergara Lope and Carlos Monge Medrano: two pioneers of high altitude medicine.

Ana Cecilia Rodríguez de Romo1.   

Abstract

Daniel Vergara Lope from Mexico and Carlos Monge Medrano from Peru were brilliant scientists in their own countries. Both scientists studied high altitude physiology and defined the physiological and anatomical mechanisms of adaptation to high elevations. The Mexican physiologist proposed his ideas 40 years before his Peruvian counterpart. This paper studies the contribution of Vergara Lope and Monge Medrano to the understanding of high altitude medicine and proposes explanations of why history has given priority to Monge, whereas Vergara Lope is relegated to anonymity.

Mesh:

Year:  2002        PMID: 12396886     DOI: 10.1089/152702902320604304

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  4 in total

Review 1.  Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.

Authors:  Víctor H Nieto Estrada; Daniel Molano Franco; Roger David Medina; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2017-06-27

2.  Interventions for preventing high altitude illness: Part 3. Miscellaneous and non-pharmacological interventions.

Authors:  Daniel Molano Franco; Víctor H Nieto Estrada; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2019-04-23

Review 3.  Interventions for preventing high altitude illness: Part 2. Less commonly-used drugs.

Authors:  Alejandro Gonzalez Garay; Daniel Molano Franco; Víctor H Nieto Estrada; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2018-03-12

4.  The Mexican response to high altitudes in the 1890s: the case of a physician and his "magic mountain".

Authors:  Ana Cecilia Rodríguez de Romo; José Rogelio Pérez Padilla
Journal:  Med Hist       Date:  2003-10       Impact factor: 1.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.